本报告导读：公司核心产品卡度尼利、依沃西双双新纳入医保，放量迎来提速；依沃西海外布局持续提速。治疗领域持续拓展，研发管线充沛。维持“增持”评级。投资要点：核心产品高速放量，维持“增持”评级。公司2024年实现收入 21.24亿元，其中扣除分销成本后的商业销售收入20.02 亿元，同比+24.88%。考虑到海外合作伙伴summit 里程碑金确认节奏的不确定性，调整2025/2026 年收入预测...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available